Aspirin Exacerbated Respiratory Disease (AERD) Polyposis

What is AERD?
AERD or Aspirin Triad (also called Samter's Triad or Aspirin Exacerbated Respiratory Disease) is a condition characterized by chronic sinusitis with nasal polyps, asthma, and aspirin sensitivity. The medication intolerance can occur with not only aspirin, but also ibuprofen and other related "NSAID" medications. In general, it is recommended to avoid these medications if you are diagnosed with this condition. The condition is treated with medications that limit its "inflammatory reaction" and sinus surgery is often helpful. Sometimes performing "aspirin desensitization" can help in management as well. The condition is known to be difficult to manage. Dr. Thomas Higgins recommends assembling a team with multidisciplinary expertise, including rhinologist, allergist, and pulmonologist, to provide the best possible care for this condition.
Chronic Rhinosinusitis with Nasal Polyps (CRSWNP)
Aspirin Triad often presents as adult-onset severe sinus infections or asthma. Extensive polyposis is present with severe inflammation of the nose and sinuses. A combination of medicines and often
endoscopic sinus surgery are necessary to reduce symptoms and improve quality of life. The techniques used for endoscopic sinus surgery in Aspirin Triad can be intricate compared to routine chronic sinusitis. Dr. Thomas Higgins recommends the surgery be performed by an experienced surgeon used to managing Aspirin Triad as scar tissue can be more prevalent and frequent repeat surgeries may be otherwise required. Expanded endoscopic surgeries of the frontal sinus (such as the modified Lothrop procedure) may greatly reduce the likelihood of needing future surgeries.


Asthma
Asthma, often with an onset in adulthood, occurs with Aspirin Triad. As a result, a multidisciplinary approach is essential to properly manage this condition. Medical therapy to help with lung function is essential along with management of sinusitis. Aspirin Triad patient with resistant problems may benefit from a therapy called aspirin desensitization or biologic therapy such as
dupilumab (Dupixent),
mepolizumab (Nucala), or
omalizumab (Xolair).